A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

NCT02016729 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancy
Cancer
Oncology
Oncology Patients
Acute Myeloid Leukemia

Interventions

DRUG: AMG 232
DRUG: Trametinib

Sponsor

Kartos Therapeutics, Inc.